Mankind Pharma Ltd.

NSE: MANKIND · Healthcare

₹2,435.60

as of 28 Sep 2026

AI verdict · 28 Sep 2026

Bearish 58% confidence

Momentum deceleration, below-average volume conviction, and pending earnings create asymmetric downside risk despite orderly technicals…

Strongest bull point

Stock outperformed NIFTY by 4.93% over 12 months with RSI at 60.3 (bullish, not overbought) and clean EMA alignment, recovering 28.41% from 52-week low on institutional accumulation.

Strongest bear point

Momentum collapsed from +28.41% (6-month) to −0.45% (3-month), volume is 27% below average, and Q2 FY27 results pending with prior-year PAT down 21.3% despite revenue growth.

Technical Forecast · next 10 trading days

Expected

₹2,527.25 +3.8%

Range

₹2,503.31 – ₹2,532.02

Technical Forecast Fundamental Debate

Free: 5 Forecasts and 5 Debates a month. Log in with your mobile number.

Every call on MANKIND, misses included

Bearish 28 Sep 2026 → now Scores 28 Oct 2026

₹2,435.60 → ₹2,435.60 0.0%

Our accuracy

Every verdict and forecast here is dated and scored when it matures — right or wrong. The first scored results publish a month after launch.

How we score →

More Healthcare